{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:28:38Z","timestamp":1790947718860,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011495","name":"Science and Technology Information Network","doi-asserted-by":"crossref","award":["Z2018188"],"award-info":[{"award-number":["Z2018188"]}],"id":[{"id":"10.13039\/501100011495","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>High-quality evidence confirms that the clinical efficacy of peramivir in severe influenza patients with primary viral pneumonia is lacking. To optimize clinical medication, we evaluate the different efficacy between peramivir and oseltamivir in the treatment of severe influenza A with primary viral pneumonia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A single-center, randomized, controlled trial was conducted during the Chinese influenza season from December 2018 to April 2019 in patients with severe influenza A with primary viral pneumonia. A total of 40 inpatients were enrolled and treated with either intravenous peramivir (300 mg, once daily for 5 days) or oral oseltamivir (75 mg, twice daily for 5 days).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The duration of influenza virus nucleic acid positivity in the oseltamivir group and the peramivir group was 2.95 days and 2.80 days, respectively. The remission times of clinical symptoms in the oseltamivir group and the peramivir group were 3.90 days and 3.25 days, respectively. In addition, the remission time of cough symptoms in the peramivir group (63.89 hours) was shorter than that in the oseltamivir group (75.53 hours). There was no significant difference between these values (P\u2005&amp;gt;\u2005.05). The remission time of fever symptoms in the oseltamivir group was 23.67 hours, which was significantly longer than that in the peramivir group (12.32 hours) (P\u2005=\u2005.034).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Peramivir is no less effective than oseltamivir in the treatment of severe influenza A with primary viral pneumonia, and patients treated with peramivir had significantly shorter remission times of fever symptoms than those treated with oseltamivir.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa562","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T19:18:57Z","timestamp":1605727137000},"source":"Crossref","is-referenced-by-count":17,"title":["Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study"],"prefix":"10.1093","volume":"8","author":[{"given":"Hong-Dou","family":"Chen","sequence":"first","affiliation":[{"name":"Suqian People\u2019s Hospital of Nanjing Drum-Tower Hospital Group, Suqian, China"},{"name":"The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[{"name":"Suqian People\u2019s Hospital of Nanjing Drum-Tower Hospital Group, Suqian, China"},{"name":"The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Le","family":"Yu","sequence":"additional","affiliation":[{"name":"Suqian People\u2019s Hospital of Nanjing Drum-Tower Hospital Group, Suqian, China"},{"name":"The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Hui","family":"Ding","sequence":"additional","affiliation":[{"name":"Suqian People\u2019s Hospital of Nanjing Drum-Tower Hospital Group, Suqian, China"},{"name":"The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Suqian People\u2019s Hospital of Nanjing Drum-Tower Hospital Group, Suqian, China"},{"name":"The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Na","family":"Wang","sequence":"additional","affiliation":[{"name":"Suqian People\u2019s Hospital of Nanjing Drum-Tower Hospital Group, Suqian, China"},{"name":"The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"2021012918362320500_CIT0001","doi-asserted-by":"crossref","first-page":"151235","DOI":"10.1155\/2014\/151235","article-title":"Efficacy and safety of clearing heat and detoxifying injection in the treatment of influenza: a randomized, double-blinded, placebo-controlled trial","volume":"2014","author":"Liu","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"2021012918362320500_CIT0002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(99)01241-6","article-title":"Influenza","volume":"354","author":"Cox","year":"1999","journal-title":"Lancet"},{"key":"2021012918362320500_CIT0003","first-page":"461","article-title":"Vaccines against in\ufb02uenza WHO position paper\u2013November 2012","volume":"87","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"2021012918362320500_CIT0004","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3349\/ymj.2017.58.4.778","article-title":"Comparison of efficacy of intravenous peramivir and oral oseltamivir for the treatment of influenza: systematic review and meta-analysis","volume":"58","author":"Lee","year":"2017","journal-title":"Yonsei Med J"},{"key":"2021012918362320500_CIT0005","doi-asserted-by":"crossref","first-page":"ofx129","DOI":"10.1093\/ofid\/ofx129","article-title":"Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with influenza A and B viruses: a multicenter randomized controlled study","volume":"4","author":"Nakamura","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021012918362320500_CIT0006","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jiac.2018.01.013","article-title":"Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan","volume":"24","author":"Ishiguro","year":"2018","journal-title":"J Infect Chemother"},{"key":"2021012918362320500_CIT0007","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jiac.2016.07.004","article-title":"Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: a drug-use investigation in patients with high risk factors","volume":"22","author":"Komeda","year":"2016","journal-title":"J Infect Chemother"},{"key":"2021012918362320500_CIT0008","doi-asserted-by":"crossref","first-page":"3859230","DOI":"10.1155\/2019\/3859230","article-title":"A retrospective analysis of three antiviral regimens of peramivir in the treatment of severe influenza a with primary viral pneumonia","volume":"2019","author":"Wang","year":"2019","journal-title":"Can Respir J"},{"key":"2021012918362320500_CIT0009","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021012918362320500_CIT0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.biopha.2017.04.091","article-title":"Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)","volume":"91","author":"Wang","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2021012918362320500_CIT0011","first-page":"1964","article-title":"Research status on pharmacological actions and in vitro and in vivo effects of arbidol against respiratory viruses","volume":"35","author":"Li","year":"2019","journal-title":"Chin J Clin Pharmacol"},{"key":"2021012918362320500_CIT0012","first-page":"48","article-title":"Efficacy of Arbidol in the prevention of virus-induced exacerbations of bronchial asthma and chronic obstructive pulmonary disease","volume":"90","author":"Titova","year":"2018","journal-title":"Ter Arkh"},{"key":"2021012918362320500_CIT0013","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/jmv.25358","article-title":"Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study","volume":"91","author":"Leneva","year":"2019","journal-title":"J Med Virol"},{"key":"2021012918362320500_CIT0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017","volume":"157","author":"Lackenby","year":"2018","journal-title":"Antiviral Res"},{"key":"2021012918362320500_CIT0015","doi-asserted-by":"crossref","first-page":"e0224683","DOI":"10.1371\/journal.pone.0224683","article-title":"Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza","volume":"14","author":"Mawatari","year":"2019","journal-title":"PLoS One"},{"key":"2021012918362320500_CIT0016","first-page":"617","article-title":"Antiviral effects of baicalin combined with peramivir against pandemic 2009 H1N1 virus in vitro and in vivo","volume":"29","author":"Li","year":"2013","journal-title":"Chinese Pharmacol Bull"},{"key":"2021012918362320500_CIT0017","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/QCO.0000000000000496","article-title":"Treatment of influenza with neuraminidase inhibitors","volume":"31","author":"Beard","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2021012918362320500_CIT0018","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1517\/14656566.2015.1066336","article-title":"Peramivir: an intravenous neuraminidase inhibitor","volume":"16","author":"McLaughlin","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2021012918362320500_CIT0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2005.10.002","article-title":"Anti-influenza virus activity of peramivir in mice with single intramuscular injection","volume":"69","author":"Bantia","year":"2006","journal-title":"Antiviral Res"},{"key":"2021012918362320500_CIT0020","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2021012918362320500_CIT0021","first-page":"989","article-title":"Research progress on peramivir of novel anti-influenza virus highly potent neuraminidase inhibitor","volume":"22","author":"Gu","year":"2013","journal-title":"Chinese J New Drugs"},{"key":"2021012918362320500_CIT0022","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2008.05.012","article-title":"Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice","volume":"80","author":"Boltz","year":"2008","journal-title":"Antiviral Res"},{"key":"2021012918362320500_CIT0023","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fmicb.2016.00450","article-title":"Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections","volume":"7","author":"Alame","year":"2016","journal-title":"Front Microbiol"},{"key":"2021012918362320500_CIT0024","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jiac.2014.07.006","article-title":"Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation","volume":"20","author":"Komeda","year":"2014","journal-title":"J Infect Chemother"},{"key":"2021012918362320500_CIT0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3851\/IMP2744","article-title":"The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice","volume":"20","author":"Tanaka","year":"2015","journal-title":"Antivir Ther"},{"key":"2021012918362320500_CIT0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/23744235.2016.1242773","article-title":"Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial","volume":"49","author":"Yoshino","year":"2017","journal-title":"Infect Dis"},{"key":"2021012918362320500_CIT0027","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1128\/AAC.00360-11","article-title":"Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021012918362320500_CIT0028","first-page":"215","article-title":"Cost-effectiveness analysis of peramivir and oseltamivir in treatment of influenza virus pneumonia in children","volume":"14","author":"Chen","year":"2019","journal-title":"China Medicine"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa562\/34386237\/ofaa562.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/1\/ofaa562\/36149866\/ofaa562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/1\/ofaa562\/36149866\/ofaa562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T18:36:36Z","timestamp":1611945396000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa562\/5989582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa562","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,11,18]]},"article-number":"ofaa562"}}